Capital Fund Management S.A. Takes Position in ImmunoGen, Inc. (IMGN)
Capital Fund Management S.A. purchased a new position in ImmunoGen, Inc. (NASDAQ:IMGN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 100,704 shares of the biotechnology company’s stock, valued at approximately $954,000. Capital Fund Management S.A. owned 0.07% of ImmunoGen at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in ImmunoGen in the second quarter worth $115,000. Signition LP acquired a new stake in ImmunoGen in the third quarter worth $115,000. MML Investors Services LLC acquired a new stake in ImmunoGen in the third quarter worth $130,000. Private Advisor Group LLC acquired a new stake in ImmunoGen in the second quarter worth $131,000. Finally, Great West Life Assurance Co. Can grew its holdings in ImmunoGen by 75.1% in the second quarter. Great West Life Assurance Co. Can now owns 15,767 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 6,763 shares during the period. Institutional investors and hedge funds own 82.72% of the company’s stock.
In other news, Director Mark Alan Goldberg purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 6th. The shares were acquired at an average cost of $5.76 per share, for a total transaction of $172,800.00. Following the completion of the acquisition, the director now owns 53,800 shares in the company, valued at $309,888. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Anna Berkenblit sold 5,851 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $8.00, for a total transaction of $46,808.00. Following the transaction, the vice president now owns 132,769 shares in the company, valued at $1,062,152. The disclosure for this sale can be found here. 4.44% of the stock is owned by company insiders.
Shares of NASDAQ IMGN opened at $5.34 on Wednesday. ImmunoGen, Inc. has a 1 year low of $5.21 and a 1 year high of $13.41. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.59 and a quick ratio of 4.56.
ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings data on Friday, November 2nd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $13.60 million. ImmunoGen had a negative net margin of 176.35% and a negative return on equity of 673.66%. The business’s revenue was up 28.2% on a year-over-year basis. During the same period last year, the company earned ($0.61) earnings per share. As a group, equities analysts expect that ImmunoGen, Inc. will post -1.24 EPS for the current year.
WARNING: “Capital Fund Management S.A. Takes Position in ImmunoGen, Inc. (IMGN)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/11/21/capital-fund-management-s-a-takes-position-in-immunogen-inc-imgn.html.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Recommended Story: Why is insider trading harmful?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.